Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

iRadimed Sees Q4 Adj EPS $0.47-$0.51 vs $0.47 Est; Sees Sales $21.400M-$22.400M vs $20.733M Est

Author: Benzinga Newsdesk | November 03, 2025 08:35am
iRadimed (NASDAQ:IRMD) is looking for Q4 Adj EPS of $0.47-$0.51 vs $0.47 analyst estimate. sees sales of $21.400 million-$22.400 million vs $20.733 million analyst estimate.

Posted In: IRMD


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist